1 published article · Updated continuously
5 trials tracked for familial chylomicronemia syndrome: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 673 citations.
Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Plozasiran demonstrated significant reductions in fasting serum triglycerides (TG) at month 10 (-85.7%, -89.5%, and 38.8%; p=0.0022) and when averaged over months 10 and 12 (-82.1%, -86.6%, and 49.5%; p=0.0055). Additionally, it significantly reduced fasting serum Apolipoprotein C3 (APOC3) at month 10 (-92.55%, -91.83%, and 19.91%; p=0.0008).
Volanesorsen showed significant reductions in fasting triglycerides by month 3, with a mean percent change of -76.5% and -49.2% across different reported cohorts [2, 4]. In one trial, Volanesorsen achieved an absolute reduction in fasting TG of -1712 mg/dL (p<0.0001) and a treatment response rate where participants reached <750 mg/dL at month 3 (p=0.0001) 2.
Olezarsen significantly reduced fasting triglycerides at both month 6 (-10.85% and -31.99%; p=0.0009) and month 12 (-22.92% and -38.50%; p=0.0044). It also demonstrated significant reductions in Apolipoprotein C-III (apoC-III) at both time points 3.
AI synthesis of 3 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
